Immune effector mechanisms in malaria

Current Opinion in Immunology

Volumn 11, Issue 4, 1999, Pages 412-419

  Good, Michael F ^a   Doolan, Denise L ^b  

^a ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^b NAVAL MEDICAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 12; MALARIA VACCINE; NITRIC OXIDE; PARASITE ANTIBODY; PARASITE ANTIGEN;

ANTIBODY RESPONSE; CELLULAR IMMUNITY; ERYTHROCYTE; HELPER CELL; HUMAN; LIFE CYCLE; MALARIA; NATURAL KILLER CELL; NONHUMAN; PARASITE IMMUNITY; PLASMODIUM; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; REVIEW; T LYMPHOCYTE SUBPOPULATION; VACCINATION;

EID: 0033178522     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(99)80069-7     Document Type: Article

References (74)

1. Nussenzweig V, Nussenzweig RS: Rationale for the development of an engineered sporozoite malaria vaccine. Adv Immunol 1989, 45:283-334.
2. Hoffman SL, Franke ED, Hollingdale MR, Druilhe P: Attacking the infected hepatocyte. In Malaria Vaccine Development: A Multi-Immune Response Approach. Edited by Hoffman SL. Washington, DC: American Society for Microbiology Press; 1996:35-76.
3. Saul A: Kinetic constraints upon the development of a malaria vaccine. Parasite Immunol 1987, 9:1-9.
4. Good MF, Berzofsky JA, Miller LH: The T cell response to the malaria circumsporozoite protein: An immunological approach to vaccine development. Annu Rev Immunol 1988, 6:663-688.
5. + T lymphocytes is required for protective immunity against Plasmodium berghei. J Immunol 1996, 156:3374-3381.
6. + T cells and antibodies required for immunity to malaria sporozoites. Nature 1987, 330:664-666.
7. + T cells. J Exp Med 1994, 180:353-358.
8. Doolan DL, Hoffman SL: Pre-erythrocytic stage immune effector mechanisms in Plasmodium spp. infections. Phil Trans Roy Soc Lond B 1997, 352:1361-1367.
9. Doolan DL, Sedegah M, Hedstrom RC, Hobart P, Charoenvit Y, Hoffman SL: Circumventing genetic restriction of protection against malaria with multi-gene DNA immunization: CD8+ T cell, interferon-g, and nitric oxide dependent immunity. J Exp Med 1996, 183:1739-1746.
10. Renggli J, Hahne M, Matile H, Betschart B, Tschoppp J, Corradin G: Elimination of P. berghei liver stages is independent of Fas (CD95/Apo-1) or perforin-mediated cytotoxicity. Parasite Immunol 1997, 19:145-148.
11. Scheller LF, Azad AF: Maintenance of protective immunity against malaria by persistent hepatic parasites derived from irradiated sporozoites. Proc Natl Acad Sci USA 1995, 92:4066-4068.
12. Sedegah M, Finkelman F, Hoffman SL: Interleukin-12 induction of interferon gamma-dependent protection against malaria. Proc Natl Acad Sci USA 1994, 91:10700-10702.
13. Hoffman SL, Crutcher JM, Puri SK, Ansari AA, Villinger F, Franke ED, Singh PP, Finkelman F, Gately MK, Dutta GP, Sedegah M: Sterile protection of monkeys against malaria after administration of interleukin-12. Nat Med 1997, 3:80-83.
14. + T cell clones against Plasmodium yoelii liver stages. J Immunol 1993, 150:1471-1478.
15. + T cell- and IFN-gamma-dependent elimination of infected hepatocytes. J Immunol 1996, 157:4061-4067.
16. Charoenvit Y, Mellouk S, Sedegah M, Toyoshima T, Leef MF, de la Vega P, Beaudoin RL, Aikawa M, Fallarme V, Hoffman SL: 17 kDa Plasmodium yoelii hepatic and erythrocytic stage protein is the target of protective antibodies. Exp Parasitol 1995, 80:419-429.
17. Stoute JA, Slaoui M, Heppner DG, Monin P, Kester K, Desmons P, Wellde BT, Garcon N, Krzych U, Marchand M et al.: A preliminary evaluation of a recombinant circumsporozoite protein vacine against Plasmodium falciparum malaria. N Engl J Med 1997, 336:86-91.
18. Stoute JA, Kester KE, Krzych U, Wellde BT, Hall T, White K, GLenn G, Ockenhouse CF, Garcon N, Schwenk R et al.: Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. J Infect Dis 1998, 178:1139-1144.
19. + CTLs are thought to be critical for protection against intracellular pathogens and some viruses but have been difficult to induce by vaccination. Furthermore, the DNA-induced CTLs were shown to be restricted by multiple HLA alleles in the same individual and this has not previously been reported for any infectious agent in man. This study promotes this potentially revolutionary vaccine technology.
20. Ockenhouse CF, Sun PF, Lanar DE, Wellde BT, Hall BT, Kester K, Stoute JA, Magill A, Krzych U, Farley L et al.: Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis 1998, 177:1664-1673.
21. + responses in mice. Proc Natl Acad Sci USA 1998, 95:3954-3959.
22. Murata K, Garcia-Sastre A, Tsuji M, Rodrigues M, Rodriguez D, Rodriguez JR, Nussenzweig RS, Palese P, Esteban M, Zavala F: Characterization of in vivo primary and secondary CD8+ T cell responses induced by recombinant influenza and vaccinia viruses. Cell Immunol 1996, 173:96-107.
23. + T cells, which to date have been difficult to induce by vaccination.
24. Sedegah M, Jones TR, Kaur M, Hedstrom R, Hobart P, Tine JA, Hoffman SL: Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc Natl Acad Sci USA 1998, 95:7648-7653. The effect on protection against malaria by immunizing with various combinations of DNA, recombinant vaccinia virus and multiple-antigen peptide was studied. Priming with plasmid DNA encoding the P. yoelii CSP followed by a single boost with a recombinant vaccinia virus NYVAC expressing the same antigen was more immunogenic (as assessed by antigen specific CTLs, IFN-γ production and antibody responses) and more protective than immunizing with DNA alone or any other combination studied.
25. Plebanski M, Gilbert SC, Schneider J, Hannan CM, Layton G, Blanchard T, Becker M, Smith G, Butcher G, Sinden RE, Hill AVS: Protection from Plasmodium berghei infection by priming and boosting T cells to a single class I-restricted epitope with recombinant carriers suitable for human use. Eur J Immunol 1998, 28:4345-4355.
26. Tsuji M, Bergmann CC, Takita-Sonoda Y, Murata K, Rodrigues EG, Nussenzweig RS, Zavala F: Recombinant Sindbis viruses expressing a cytotoxic T-lymphocyte epitope of a malaria parasite or of influenza virus elicit protection against the corresponding pathogen in mice. J Virol 1998, 72:6907-6910.
27. + T cell-mediated protective immunity against malaria. J Immunol 1997, 158:1268-1274.
28. Berzins K, Perlmann P: Malaria vaccines: Attacking infected erythrocytes. In Malaria Vaccine Development: A Multi-Immune Response Approach. Edited by Hoffman SL. Washington, DC: American Society for Microbiology Press; 1996:105-143.
29. Freeman RR, Parish CR: Plasmodium yoelii: Antibody and the maintenance of immunity in BALB/c mice. Exp Parasitol 1981, 52:18-24.
30. von der Weid T, Honarvar N, Langhorne J: Gene-targeted mice lacking B cells are unable to eliminate a blood stage malaria infection. J Immunol 1996, 156:2510-2516.
31. Grun JL, Weiudanz WP: Antibody-independent immunity to reinfection malaria in B-cell-deficient mice. Infect Immun 1983, 41:1197-1204.
32. Brake D, Long CA, Weidanz WP: Adoptive protection against Plasmodium chabaudi adami malaria in athymic nude mice by a cloned T cell line. J Immunol 1988, 140:1989-1993.
33. HD mouse. J Immunol 1994, 154:4558-4562.
34. Amante FH, Good MF: Prolonged Th1-like response generated by a Plasmodium yoelii-specific T cell clone allows complete clearance of infection in reconstituted mice. Parasite Immunol 1997, 19:111-126.
35. H2 cells in a rodent malaria infection. Science 1993, 260:1931-1934.
36. Stevenson MM, Tam MF, Wolf SF, Sher A: IL-12-induced protection against blood-stage plasmodium chabaudi AS requires IFN-g and TNF-a and occurs via a nitric oxice-dependent mechanism. J Immunol 1995, 155:2545-2556.
37. + T cells specific for parasite antigens can reduce parasitemia but also contribute to weight loss and anemia. The role of cytokines and nitric oxide was explored by blocking studies in vivo.
38. van der Heyde HC, Elloso MM, Chang W-L, Kaplan M, Manning DD, Weidanz WP: γδ T cells function in cell-mediated immunity to acute blood-stage Plasmodium chabaudi adami malaria. J Immunol 1995, 154:3985-3990.
39. Seixas EMG, Langhorne J: γδ T cells contribute to control of chronic parasitemia in Plasmodium chabaudi infections in mice. J Immunol 1999, 162:2837-2841. This study shows that higher parasite densities result when there is an absence, or a reduction, in γδ T cells in mice lacking B cells. Thus, γδ T cells play an important part in CMI - at least in the mouse model.
40. Favila-Castillo L, Monroy-Ostria A, Kobayashi E, Hirunpetcharat C, Kamada N, Good MF: Protection of rats against malaria by a transplanted immune spleen. Parasite Immunol 1996, 18:325-331.
41. + T cells specific for P. berghei are deleted, apparently by apoptosis, within 4-7 days post-infection. However, T cells specific for ovalbumin are not affected. This study, in an adoptive transfer model in nude mice, does provide a possible insight into an effective parasite strategy to limit the antiparasite immune response.
42. Cohen S, McGregor IA, Carrington S: Gamma-globulin and acquired immunity to human malaria. Nature 1961, 192:733-737.
43. Fried M, Nosten F, Brockman A, Brabin BJ, Duffy PE: Maternal antibodies block malaria. Nature 1998, 395:851-852. Parasites adhere to chondroitin sulphate A in the placenta. Antiadhesion antibodies appear during second and subsequent pregnancies, are strain independent and are associated with reduced pathology. The authors conclude that the susceptibility to malaria in first pregnancies is related to a lack of these antibodies and that this observation may provide a strategy for producing a malaria vaccine.
44. Bull PC, Lowe BS, Kortok M, Molyneux CS, Newbold CI, Marsh K: Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria. Nat Med 1998, 4:358-360. Variant antigens expressed on infected red cells are shown to be critical targets for clearing infections in children. While expressing antibody specificities for other strains, children largely do not have antibodies specific for the strains that are responsible for the current clinical attack.
45. Fell AH, Currier J, Good MF: Inhibition of Plasmodium falciparum growth in vitro by CD4+ and CD8+ T cells from non-exposed donors. Parasite Immunol 1994, 16:579-586.
46. Chandramohan D, Greenwood BM: Is there an interaction between human immunodeficiency and Plasmodium falciparum? Int J Epidemiology 1998, 27:296-301.
47. Holder AA: Malaria vaccines. Proc Natl Acad Sci USA 1999, 96:1167-1169.
48. Anders RF, Saul AJ: Candidate antigens for an asexual blood stage vaccine against falciparum malaria. In Molecular Immunological Considerations in Malaria Vaccine Development. Edited by Good MF, Saul AJ. Boca Raton, Florida: CRC Press; 1994:169-208.
49. Taylor RR, Allen SJ, Greenwood BM, Riley EM: IgG3 antibodies to Plasmodium falciparum Merozoite Surface Protein 2 (MSP2): Increasing prevalence with age and association with clinical immunity to malaria. Am J Trop Med Hyg 1998, 58:406-413. A study showing that the presence of IgG3 antibodies to a serogroup of MSP2 - if present before the transmission season in The Gambia - was negatively associated with risk of clinical malaria during the transmission season whereas IgG1 antibodies to a different serogroup of MSP2 were positively associated with risk of clinical malaria. The findings are interesting, firstly, in that antibody subclass (which is important for antibody function) is critical and, secondly, in identifying MSP2 as a potential target for modulating the outcome.
50. Sharma P, Kumar A, Singh B, Bharadwaj A, Sailaja VN, Adak T, Kushwaha A, Malhotra P, Chauhan VS: Characterization of protective epitopes in a highly conserved Plasmodium falciparum antigenic protein containing repeats of acidic and basic residues. Infect Immun 1998, 66:2895-2904.
51. Siddique AB, Ahlborg N, Wahlin Flyg B, Perlmann P, Berzins K: Antibodies to sequences in a non-repeat region of plasmodium falciparum antigen Pf155/RESA inhibit either cytoadherence or parasite growth in vitro. Parasitology 1998, 117:209-216.
52. Theisen M, Soe S, Oeuvray C, Thomas AW, Vuust J, Danielsen S, Jepsen S, Druilhe P: The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro. Infect Immun 1998, 66:11-17.
53. Amante FH, Crewther PE, Anders RF, Good MF: A cryptic T cell epitope on the apical membrane antigen 1 of Plasmodium chabaudi adami can prime for an anamnestic antibody response: Implications for malaria vaccine design. J Immunol 1997, 159:5535-5544.
54. Anders RF, Crewther PE, Edwards S, Margetts M, Matthew ML, Pollock B, Pye D: Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi. Vaccine 1998, 16:240-247. A homologue of a leading malaria vaccine candidate can induce protection in mice but the antigen must be folded correctly. Antibodies to the antigen can passively cure an established infection.
55. Holder AA: Preventing merozoite invasion of erythrocytes. In Malaria Vaccine Development: A Multi-Immune Response Approach. Edited by Huffman SL. Washington, DC: American Society for Microbiology Press; 1996:77-104.
56. Good MF, Kaslow DC, Miller LH: Pathways and strategies for developing a malaria blood-stage vaccine. Annu Rev Immunol 1998, 16:57-87. A recent review outlining strategy and critical pathways for developing a vaccine, with an emphasis on MSP1 and AMA1. Obstacles to vaccine development are discussed.
57. Branch OH, Udhayakumar V, Hightower AW, Oloo AJ, Hawley WA, Nahlen BL, Bloland PB, Kaslow DC, Lal AA: A longitudinal investigation of IgG and IgM antibody responses to the merozoite surface protein-1 19-kilodalton domain of Plasmodium falciparum in pregnant women and infants: Associations with febrile illness, parasitemia, and anemia. Am J Trop Med Hyg 1998, 58:211-219.
58. Tian JH, Kumar S, Kaslow DC, Miller LH: Comparison of protection induced by immunization with recombinant proteins from different regions of merozoite surface protein 1 of Plasmodium yoelii. Infect Immun 1997, 65:3032-3036.
59. Yang C, Collins WE, Sullivan JS, Kaslow DC, Xiao L, Lal AA: Partial protection against Plasmodium vivax blood-stage infection in Saimiri monkeys by immunization with a recombinant C-terminal fragment of merozoite surface protein 1 in block copolymer adjuvant. Infect Immun 1999, 6:342-349.
60. Miller LH, Roberts T, Shahabuddin M, McCutchan TF: Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1). Mol Biochem Parasitol 1993, 59:1-14.
61. Jongwutiwes S, Tanabe K, Kanbara H: Sequence conservation in the C-terminal part of the precursor to the major merozoite surface proteins (MSP1) of Plasmodium falciparum from field isolates. Mol Biochem Parasitol 1993, 59:95-100.
62. Majarian WR, Daly TM, Weidanz WP, Long CA: Passive immunization against murine malaria with an IgG3 monoclonal antibody. J Immunol 1984, 132:3131-3137.
63. 19) of Plasmodium yoelii expressed in saccharomyces cerevisiae: Correlation of protection with antigen-specific antibody titer, but not with effector CD4+ T cells. J Immunol 1997, 159:3400-3411.
64. 19-specific CMI can control parasite growth, at least for P. yoelii in the mouse.
65. 19, do not need to engage this mechanism of action for their antiparasite effect.
66. Daly TM, Long CA: Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria. J Immunol 1995, 155:236-243.
67. 19) induces protective immunity to blood stage malaria infection in mice. Parasite Immunol 1998, 20:413-420.
68. Hirunpetcharat C, Vukovic P, Liu XQ, Kaslow DC, Miller LH, Good MF: Absolute requirement for an active immune response involving B cells and helper T cells in immunity to Plasmodium yoelii passively acquired with antibodies to the 19 kD carboxylterminal fragment of merozoite surface protein-1. J Immunol 1999, 162:7309-7314.
69. Riley EM, Morris-Jones S, Blackman MJ, Greenwood BM, Holder AA: A longitudinal study of naturally acquired cellular and humoral immune responses to a merozoite surface protein (MSP1) of Plasmodium falciparum in an area of seasonal malaria transmission. Parasite Immuol 1993, 15:513-524.
70. Cavanagh DR, Elhassan IM, Roper C, Robinson VJ, Giha H, Holder AA, Hviid L, Theander TG, Arnot DE, McBride JS: A longitudinal study of type-specific antibody responses to Plasmodium falciparum merozoite surface protein-1 in an area of unstable malaria in sudan. J Immunol 1998, 161:347-359.
71. Schofield L, McConville MJ, Hansen D, Campbell AS, Fraser-Reid B, Grusby MJ, Tachado SD: CD1d-restricted immunoglobulin G formation to GPI-anchored antigens mediated by NKT cells. Science 1999, 283:225-229.
72. Daly TM, Long CA: Influence of adjuvants on protection induced by a recombinant fusion protein against malarial infection. Infect Immun 1996, 64:2602-2608.
73. Ling IT, Ogun SA, Momin P, Richards RL, Garçon N, Cohen J, Ballou WR, Holder AA: Immunization against the murine malaria parasite Plasmodium yoelii using a recombinant protein with adjuvants developed for clinical use. Vaccine 1997, 15:1562-1567.
74. Kang Y, Calvo PA, Daly TM, Long CA: Comparison of humoral immune responses elicited by DNA and protein vaccines based on merozoite surface protein-1 from Plasmodium yoelii, a rodent malaria parasite. J Immunol 1998, 161:4211-4219.